Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anna Bohdanowicz-Pawlak is active.

Publication


Featured researches published by Anna Bohdanowicz-Pawlak.


Gynecological Endocrinology | 2004

Serum lipid peroxides and total antioxidant status in postmenopausal women on hormone replacement therapy

Bednarek-Tupikowska G; Krzysztof Tupikowski; B. Bidzińska; Anna Bohdanowicz-Pawlak; J. Antonowicz-Juchniewicz; B. Kosowska; Andrzej Milewicz

Estradiol (E2) has antioxidant properties. The role of progestins in antioxidant defense is still unknown. We have evaluated the influence of E2 and E2 plus medroxyprogesterone acetate (MPA) on serum lipid peroxide (LPO) levels, a marker of free radical reactions, and serum total antioxidant status (TAS) in postmenopausal women. Subjects consisted of 26 women with surgical menopause, before and after 4 months of estrogen replacement therapy (ERT; E2), and 54 women with natural menopause on hormone replacement therapy (HRT; E2 plus MPA). Forty premenopausal women served as a control group. Serum E2 was estimated by radioimmunoassay, follicle-stimulating hormone by IRMA methods, LPO and TAS by colorimetric methods. Before therapy, LPO levels in the postmenopausal women were significantly higher (p < 0.001) than in the control group. After both ERT and HRT, LPO decreased significantly and did not differ between both groups and the control group. TAS was significantly lower in postmenopausal women (p < 0.001) than in the control group before therapy. After both ERT and HRT, TAS increased significantly and did not differ between both groups and the control group. We conclude that oxidative stress is increased after menopause. ERT and HRT inhibit the generation of free radicals and raise antioxidant potential to the levels found in premenopausal women. MPA did not influence the antioxidant action of E2.


Gynecological Endocrinology | 2008

Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment.

Joanna Jakubowska; Anna Bohdanowicz-Pawlak; Andrzej Milewicz; Jadwiga Szymczak; Bednarek-Tupikowska G; Marek Demissie

Objectives. Most research confirms that metformin therapy has a positive influence on cardiovascular risk factors (CVRF) such as dyslipidemia, insulin resistance and hyperandrogenism in polycystic ovary syndrome (PCOS). The aims of the present study were to establish other CVRF, such as plasma adiponectin, tumor necrosis factor-α (TNFα), interleukin-6 (IL-6) and C-reactive protein (CRP) levels, in obese premenopausal women with PCOS and to investigate the effect of metformin treatment on these factors. Materials and methods. The study group consisted of 29 PCOS woman with body mass index (BMI) >25 kg/m2. They were treated over 6 months with 500 mg metformin twice daily. Twenty-nine healthy individuals matched for age and BMI were controls. Adiponectin, TNFα, IL-6 and CRP levels were examined in all PCOS (before and after treatment) and control women. Results. In the PCOS group significantly lower plasma adiponectin and TNFα levels were observed, whereas there were no differences in plasma IL-6 and CRP levels between PCOS and control groups. Plasma adiponectin increased significantly after metformin treatment, but levels of inflammatory factors did not change.


Thyroid Research | 2013

Effects of radioiodine administration on serum concentrations of matrix metalloproteinases, adiponectin and thrombospondin-1

Andrzej Lewiński; Anna Brona; Krzysztof Lewandowski; Diana Jędrzejuk; Anna Bohdanowicz-Pawlak; Elzbieta Skowronska-Jozwiak; Małgorzata Bieńkiewicz; Andrzej Milewicz

BackgroundIn order to assess safety of radioactive iodine administration in the treatment of thyrotoxicosis, we measured concentrations of matrix metalloproteinase-2 (MMP-2), its main inhibitor – TIMP-2 (tissue inhibitor of MMP-2), matrix metalloproteinase-9 (MMP-9), its main inhibitor – TIMP-1, adiponectin, as well as pro-inflammatory and procancerogenic thrombospondin-1 (TSP-1).Design and patientsThe study involved 23 patients treated with radioiodine for thyrotoxicosis. Serum concentrations of TSH, free T4, free T3, MMP-2, MMP-9, TIMP-1, TIMP-2, total adiponectin and TSP-1 were measured by immunoassays just before radioiodine administration (visit 1), and subsequently, after 7 days (visit 2), 3 months (visit 3), 6 to 8 months (visit 4) and 15–18 months after radioiodine administration (visit 5).ResultsThere were no acute changes in serum concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2, adiponectin and TSP-1 (visit 1 vs. 2). Subsequently, there was an increase in MMP-2 (from 393±106 ng/ml to 774±424 ng/ml), TIMP-1 (from 177±76 ng/ml to 296±118 ng/ml), and adiponectin (from 16442±9490 ng/ml to 23518±9840 ng/ml), visit 1 to 5, respectively (p < 0.01). Further analysis revealed no significant change in MMP-2/TIMP-2 ratio, but there was a significant decrease in MMP-9/TIMP-1 ratio (p < 0.05), suggestive of possible decrease in free MMP-9 concentrations.ConclusionsOur data reveal a significant and sustained increase in serum adiponectin, as well as possible decrease of free MMP-9 concentration after radioiodine administration. In contrast, there was no significant change of TSP-1. This might indicate overall safety of radioiodine treatment of thyrotoxicosis in terms of the risks of subsequent cardiovascular and neoplastic disease.


Thyroid Research | 2013

Do thyroid peroxidase antibodies influence risk of cardiovascular diseases before and after treatment of hyperthyroidism

Anna Brona; Anna Bohdanowicz-Pawlak; Joanna Jakubowska; Diana Jędrzejuk; Andrzej Milewicz

We have evaluated how levels of predictors of the cardiovascular risk such as: glucose, insulin, total cholesterol, high-density cholesterol, low-density cholesterol and triglycerides as well as adiponectin, fibrinogen, D-Dimers and CRP changed 24-28 weeks after treatment of hyperthyroidism in women with low and high titer of antibodies, and if their levels were different in these groups before and after treatment of hyperthyroidism. We compared also fT4 level before and after treatment in study groups. We investigated 35 postmenopausal women (non-smoking, aged 51-69 years) with subclinical and overt hyperthyroidism. We divided them into two groups according to titer of thyroid peroxidase antibodies: with low titer of antibodies (27 women) and high titer of antibodies (8 women). Statistical analysis revealed no difference in lipids profile, coagulation-fibrinolytic system, glucose, insulin, CRP and adiponectin level (before and after treatment) between groups with low and high titer of antibodies. No difference in fT4 level before and after treatment was found. In women with low titer of antibodies significant decrease was observed only in fT4 level (20.38 vs. 13.23 ng/ml). Levels of other factors did not differ before and after treatment. Triglycerides level decreased (133.00 vs. 89.13 mg/dl) and CRP level increased (2.95 vs. 4.48 mg/l) significantly after treatment in women with high titer of antibodies. Data suggest that it is more difficult to become euthyroid for women with hyperthyroidism and high titer of antibodies (there is no significant difference between fT4 level before and after treatment). Changes in metabolic profile and increase in inflammatory process are observed in women with hyperthyroidism and high titer of antibodies.


Gynecological Endocrinology | 1999

The influence of dehydroepiandrosterone on histology of selected organs in rabbits on an atherogenic diet.

Bednarek-Tupikowska G; J. Kuryszko; B. Kosowska; Anna Bohdanowicz-Pawlak; Andrzej Milewicz

The influence of dehydroepiandrosterone (DHEA) in fodder on the histology of selected organs in rabbits with induced hypercholesterolemia and in healthy rabbits was studied. Rabbits were randomly assigned into four groups: (1) control; (2) atherogenic diet; (3) atherogenic diet with addition of DHEA; (4) normal diet with addition of DHEA. After 12 weeks, the rabbits were bled. Tissue samples were collected, fixed in a 0.4% solution of buffered formalin, dehydrated and embedded in paraffin. Fragments of 5-7 microns were stained with hematoxylin and eosin as well as according to the van Gieson method. Histological analysis showed features of steatosis and intense degenerative changes in analyzed organs of animals from group 2, i.e. liver, kidneys, adrenal glands, lungs and bone. The degenerative changes in the group which in addition to a fat-rich diet received DHEA, were similar to group 2, but much less intense. Histological pictures of organs of the rabbits which received DHEA and normal diet did not differ significantly from the control group. In animals with experimental hyperlipidemia, DHEA acts protectively, decreasing degenerative changes in internal organs caused by an atherogenic diet. DHEA does not change the histological picture of organs in healthy animals.


Medical Science Monitor | 2000

Influence of dehydroepiandrosterone on platelet aggregation, superoxide dismutase activity and serum lipid peroxide concentrations in rabbits with induced hypercholesterolemia.

Bednarek-Tupikowska G; Gosk I; Szuba A; Anna Bohdanowicz-Pawlak; Kosowska B; Bożena Bidzińska; Andrzej Milewicz


Endokrynologia Polska | 2013

Subclinical Cushing’s syndrome in adrenal incidentalomas — possible metabolic consequences

Anna Bohdanowicz-Pawlak; Jadwiga Szymczak; Ewa Waszczuk; Marek Bolanowski; Grażyna Bednarek-Tupikowska


Medical Science Monitor | 2008

The correlations between endogenous dehydroepiandrosterone sulfate and some atherosclerosis risk factors in premenopausal women

Bednarek-Tupikowska G; Urszula Tworowska-Bardzińska; Krzysztof Tupikowski; Anna Bohdanowicz-Pawlak; Jadwiga Szymczak; Eliza Kubicka; Anna Skoczyńska; Andrzej Milewicz


Endokrynologia Polska | 1993

The efficacy, tolerability and safety of Parlodel LAR versus Parlodel in hyperprolactinemia.

Marek Bolanowski; Andrzej Milewicz; Anna Bohdanowicz-Pawlak; Bednarek-Tupikowska G; Jedrzejak Ja; Lancranjan I


Endokrynologia Polska | 1993

[Results of treatment for acromegaly with long-acting bromocriptine (Parlodel LAR)].

Bednarek-Tupikowska G; Anna Bohdanowicz-Pawlak; Marek Bolanowski; Jedrzejak Ja; Andrzej Milewicz

Collaboration


Dive into the Anna Bohdanowicz-Pawlak's collaboration.

Top Co-Authors

Avatar

Andrzej Milewicz

Wrocław Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marek Bolanowski

Wrocław Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anna Brona

University of Wrocław

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrzej Lewiński

Medical University of Łódź

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge